Table 1.
FSGS | Alport syndrome | |||||||
---|---|---|---|---|---|---|---|---|
CTRL | ADR | CD | ADR+CD | Col4a3+/+ NS | Col4a3+/+ CD | Col4a3−/− NS | Col4a3−/− CD | |
Cholesterol, mg/dL | 92.7±2.7 | 113.2±14.7 | 89.8±0.3 | 120.3±13.0& | 117.9±3.4 | 131.3±4.7 | 203.5±10.0*** | 145.5±7.6** |
HDL mg/dL | 51.7±22.4 | 98.2±17.1 | 57.0±10.4 | 112.0±12.3 | 129.8±6.7 | 137.0±6.1 | 162.8±6.7# | 138.3±5.4* |
LDL mg/dL | BDL | −5.0±3.7 | BDL | −3.3±0.5 | 5.4±0.3 | 5.8±0.9 | 14.9±1.2# | 10.0±2.0 |
Triglycerides mg/dL | 46.7±15.5 | 83.0±8.6 | 54.0±5.0 | 58.3±3.8 | 61.6±2.9 | 63.0±2.8 | 81.6±6.6 | 98.3±17.0 |
VLDL mg/dL | 12.0±2.0 | 15.4±1.9 | 11.0±1.1 | 11.7±0.9 | 14.6±1.4 | 16.0±1.4 | 13.7±1.0 | 19.8±3.5* |
Data are mean ± SD. ADR – adriamycin; CD – 2-hydroxypropyl-β-cyclodextrin (HPβCD); CTRL – control; NS – normal saline solution; HDL – high density lipids, LDL – low density lipids; VLDL – very low density lipids; BDL – below detection level.
p<0.05
p<0.01, when comparing CD treated vs. non-treated
p<0.01
p<0.001, when comparing knockout vs. controls
p<0.05, when comparing ADR+CD vs. CD group.